These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22023903)

  • 21. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy for treatment of osteoporosis: A review.
    Pinkerton JV; Dalkin AC
    Am J Obstet Gynecol; 2007 Dec; 197(6):559-65. PubMed ID: 18060937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The influence of teriparatide (Forteo) on low back pain incidence in postmenopausal osteoporotic woman].
    Vlak T; Labar L; Sapina G; Novak A; Sabić M
    Reumatizam; 2007; 54(2):93-5. PubMed ID: 18351155
    [No Abstract]   [Full Text] [Related]  

  • 25. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

  • 26. [Up-to-date treatments for osteoporosis].
    Bors K
    Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months.
    Jobke B; Muche B; Burghardt AJ; Semler J; Link TM; Majumdar S
    Calcif Tissue Int; 2011 Aug; 89(2):130-9. PubMed ID: 21626160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].
    Skiba K; Adamczak M; Wiecek A
    Przegl Lek; 2011; 68(7):391-5. PubMed ID: 22010479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2014 Sep; 56(1452):91-6. PubMed ID: 25247344
    [No Abstract]   [Full Text] [Related]  

  • 30. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.
    Lyritis G; Marin F; Barker C; Pfeifer M; Farrerons J; Brixen K; del Pino J; Keen R; Nickelsen TN;
    Curr Med Res Opin; 2010 Aug; 26(8):1799-807. PubMed ID: 20482322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
    Brufsky AM
    Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.
    Lindsay R; Cosman F; Zhou H; Bostrom MP; Shen VW; Cruz JD; Nieves JW; Dempster DW
    J Bone Miner Res; 2006 Mar; 21(3):366-73. PubMed ID: 16491283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of postmenopausal osteoporosis.
    Andreopoulou P; Bockman RS
    Annu Rev Med; 2015; 66():329-42. PubMed ID: 25386933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
    Miller RG
    Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
    Bilezikian JP
    Curr Osteoporos Rep; 2008 Mar; 6(1):24-30. PubMed ID: 18430397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
    Takada J; Iba K; Yamashita T; Yoshizaki T
    Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.
    Dempster DW; Zhou H; Recker RR; Brown JP; Recknor CP; Lewiecki EM; Miller PD; Rao SD; Kendler DL; Lindsay R; Krege JH; Alam J; Taylor KA; Janos B; Ruff VA
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1353-63. PubMed ID: 26859106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.